Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for PLX4032 (compound)
Most Correlated Studies
- Malignant melanoma COLO829 cells depleted of MITF and/or treated with vemurafenib
- Melanoma WM 164 cells treated with PLX4032
- Melanoma A375 cells treated with the BRAFV600E inhibitor vemurafenib
- Melanoma Melmet5 cells monocultured or cocultured with lung fibroblasts and treated with vemurafenib
- Cutaneous squammous cell carcinoma B9 cells with HRAS-Q61L treated with RAF inhibitors
Most Relevant Literature
- Vitamin C sensitizes BRAFV600E thyroid cancer to PLX4032 via inhibiting the feedback activation of M…
- Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX472…
- Involvement of superoxide and nitric oxide in BRAF(V600E) inhibitor PLX4032-induced growth inhibitio…
- HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physi…
- METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation.
Most Relevant Clinical Trials
- Safety Study of PLX4032 in Patients With Solid Tumors
- BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
- A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
- A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
- A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic …
